Novartis

Entrepreneur and Cost Plus Drugs cofounder Mark Cuban (right) speaks with Andrew Nusca, editorial director of Fortune’s Brainstorm series, at a Brainstorm Tech dinner on Monday, Jan. 6, 2025, in Las Vegas.
Health

Mark Cuban once helped his college friend save almost $10,000 on prescriptions after a ‘horrific car accident’

By
January 7, 2025
Swiss pharma giant Novartis says 30 pipeline drugs with ‘significant potential’ will drive long-term growth
Finance

Swiss pharma giant Novartis says 30 pipeline drugs with ‘significant potential’ will drive long-term growth

By
November 21, 2024
Fortune Global Forum 2024 Tuesday, November 12, 2024 New York, NY 12:05 PM – 1:20 PM LUNCH STRATEGY SESSIONS PIONEERING TECH THAT DELIVERS NEXT-GEN SOLUTIONS As technology advances, the need to bring new classes of products to customers in both agile and innovative ways becomes crucial. Escalating trade tensions, climate change, geopolitical turmoil, and labor disputes are also throwing traditional commercialization models into disarray. These conflicts are, in turn, putting pressure on production lines, supply chains, and infrastructure, with domino effects across industries and borders. To remain competitive, business leaders must navigate these new complexities in order to deliver everything from life-saving medications to consumer products on time–and at scale. In this session, we’ll learn how some companies have been able to deliver next gen solutions while meeting the demands of a changing marketplace. Presented by Novartis Discussion Leaders: Victor Bulto, President, U.S., Novartis Jennifer Nuckles, Chief Executive Officer, R-Zero Charles van der Steene, President, North America, Maersk Krish Venkataraman, President, Dataiku Moderator: Alex Wood Morton, Fortune Photograph by Michael O’Shea for Fortune
Conferences

From biopharma to real estate to shipping, top CEOs insist AI is worth the hype

By
November 15, 2024
Pascal Soriot, chief executive officer of Astrazeneca Plc, arrives at the CEO council at the Great Hall of the People in Beijing, Chin
Success

Major investors say AstraZeneca boss is ‘massively underpaid’ on $21.5 million salary, despite earning more than double Novo Nordisk’s CEO

By
April 10, 2024
Stock traders from various companies work in five circular and one semi-circular trading floor at the Frankfurt Stock Exchange.
Finance

Meet Europe’s answer to the ‘Magnificent 7’—the high-flying ‘Granolas’ that Goldman Sachs is betting will prosper in the continent’s flatlining economy

By
March 3, 2024
How to talk about a war at work: Sometimes the bravest stance is not taking a stance
Leadership

How to talk about a war at work: Sometimes the bravest stance is not taking a stance

By
November 29, 2023
The world’s 10 biggest pharmaceutical companies raked in over $700 billion in revenue in 2021
Finance

The world’s 10 biggest pharmaceutical companies raked in over $700 billion in revenue in 2021

By
August 15, 2022
Novartis CEO Vas Narasimhan
Leadership

Novartis to cut as many as 8,000 jobs under plan to save $1 billion by 2024

By Eric Pfanner and Bloomberg
June 29, 2022
Brainstorm Health 2020-Giovanni Caforio-Vas Narasimhan
Conferences

Will the pharmaceutical industry keep collaborating after COVID-19? Novartis and Bristol Myers Squibb CEOs say it has to

By
July 7, 2020
Novartis CEO explains why the wait for a coronavirus vaccine is so long
Leadership

Novartis CEO explains why the wait for a coronavirus vaccine is so long

By
June 2, 2020
Novartis Zolgensma Gene Therapy Sales
Newsletters

Why a drug that costs $2.1 million per dose is on a sales streak

By
January 29, 2020
Novartis Amarin Cholesterol Drugs
Newsletters

Novartis’ $9.7 Billion Deal Sets off Heart Drug Wars

By
November 25, 2019
American Vasant Narasimhan, CEO of Swiss pharmaceutical and drug maker Novartis speaks during a conference at the Fortune Global Forum event in Paris on Nov. 18, 2019. (Photo by ERIC PIERMONT / AFP) (Photo by ERIC PIERMONT/AFP via Getty Images)
International

Novartis Bets Big on Cholesterol Drug With $9.7 Billion Buyout of Medicines Co.

By James Paton and Bloomberg
November 25, 2019
Novartis Zolgensma brother scientists
Newsletters

The Fallout from Novartis’ Alleged Data Manipulation: Brainstorm Health

By
August 14, 2019
Novartis Zolgensma FDA
Health

Novartis Defends $2.1 Million Gene Therapy After FDA Data Manipulation Claims—Brainstorm Health

By
August 6, 2019

Most Popular